Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Inclusion Criteria: 1. Diagnosed as mCRPC according to EAU-ESTRO-SIOG 2016 and PSA \> 10ng/ml; 2. No previous treatment with novel hormonal therapy; 3. ECOG 0-2; 4. Normal organ function, WBC \>= 3000/mm3 or Neutrophil \>= 1500/mm3; 5. Aged 18 to 85 years old when issuing written informed consent; 6. Life expectancy \> 12 months. 7. Consent and able to carry out follow-up visit and cooperate with all other study procedures. Exclusion Criteria: 1. Severe disease or other medical conditions suggesting a high risk of death within 1 year, which may interfere with follow-up. Decided by investigator; 2. Diagnosed with any other malignant tumor within 3 years before enrollment; 3. Unable to provide necessary follow-up information; 4. Other conditions that are judged as ineligible by the investigator.